M. Baumann

发表

Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

I. Petersen, R. Beroukhim, H. Groen, 2010, Science Translational Medicine.

Discovery of a Novel Hedgehog Signaling Pathway Inhibitor by Cell-based Compound Discovery and Target Prediction

G. Schneider, H. Waldmann, B. Klebl, 2017 .

Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.

J. Hengstler, C. Schultz-Fademrecht, D. Rauh, 2017, Journal of medicinal chemistry.

C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria.

A. Więcek, H. Haller, D. Eulberg, 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer.

J. Hengstler, W. Uhl, A. Tannapfel, 2019, Cancer research.

Small-Molecule Inhibition of the UNC119-Cargo Interaction.

A. Wittinghofer, H. Waldmann, C. Ehrt, 2017, Angewandte Chemie.

Blocking the Farnesyl Pocket of PDEδ Reduces Rheb-Dependent mTORC1 Activation and Survival of Tsc2-Null Cells

A. F. Castro, R. Pincheira, B. Klebl, 2022, Frontiers in Pharmacology.

Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study

R. Greil, R. Foà, I. Yakoub-Agha, 2017, Leukemia.

In vivo proof‐of‐concept for two experimental antiviral drugs, both directed to cellular targets, using a murine cytomegalovirus model

M. Marschall, B. Kaufer, T. Bäuerle, 2019, Antiviral research.

Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing Inhibitors.

M. Sos, P. Nussbaumer, B. Klebl, 2022, Journal of medicinal chemistry.

Potent Anti-Leukemic Activity of a Novel Cdk9 Inhibitor in Preclinical CLL Mouse Models

J. Dürig, U. Dührsen, C. Schultz-Fademrecht, 2011 .

Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer

H. Briem, P. Lienau, P. Nussbaumer, 2017, ChemMedChem.

Covalent Protein Labeling at Glutamic Acids.

A. Wittinghofer, H. Waldmann, E. Fansa, 2017, Cell chemical biology.

Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S† †Electronic supplementary information (ESI) available. CCDC 1876852. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c9sc03445e

J. Hengstler, R. Zahedi, L. Kollipara, 2019, Chemical science.

Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors

B. Wittig, M. Baumann, D. Oswald, 2019, Oncoimmunology.

A Novel CDK7 Inhibitor of the Pyrazolotriazine Class Exerts Broad-Spectrum Antiviral Activity at Nanomolar Concentrations

K. Korn, B. Klebl, Jens Milbradt, 2015, Antimicrobial Agents and Chemotherapy.

Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth

C. Lindskog, J. Rahnenführer, K. Edlund, 2023, Journal of Experimental & Clinical Cancer Research.

Development of Pyridazinone Chemotypes Targeting the PDEδ Prenyl Binding Site.

A. Wittinghofer, H. Waldmann, P. Nussbaumer, 2017, Chemistry.

Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia

B. Klebl, J. Dürig, U. Dührsen, 2018, Oncotarget.

In Vitro Characterization of Small‐Molecule Kinase Inhibitors

D. Hafenbradl, L. Neumann, M. Baumann, 2011 .

Part One Hit Finding and Profiling for Protein Kinases : Assay Development and Screening , Libraries

D. Hafenbradl, L. Neumann, M. Baumann, 2010 .

Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects

N. Halama, D. Jäger, D. Eulberg, 2021, Journal for ImmunoTherapy of Cancer.

Targeting Her2-insYVMA with Covalent Inhibitors - A Focused Compound Screening and Structure-Based Design Approach.

W. V. van Otterlo, D. Rauh, S. Bauer, 2020, Journal of medicinal chemistry.

C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria

A. Więcek, H. Haller, D. Eulberg, 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Dynarrestin, a Novel Inhibitor of Cytoplasmic Dynein.

H. Schöler, T. Schroer, H. Waldmann, 2018, Cell chemical biology.

Amorfrutins are potent antidiabetic dietary natural products

K. Büssow, S. Sauer, A. Freiwald, 2012, Proceedings of the National Academy of Sciences.

Discovery of the Hedgehog Pathway Inhibitor Pipinib that Targets PI4KIIIß

H. Schöler, H. Waldmann, Takanari Inoue, 2019, Angewandte Chemie.

Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia

R. Foà, M. Gobbi, M. Steurer, 2019, Haematologica.

Discovery of a Novel Inhibitor of the Hedgehog Signaling Pathway through Cell-based Compound Discovery and Target Prediction.

Herbert Waldmann, Gisbert Schneider, Slava Ziegler, 2017, Angewandte Chemie.

A PDE6δ-KRas Inhibitor Chemotype with up to Seven H-Bonds and Picomolar Affinity that Prevents Efficient Inhibitor Release by Arl2.

P. Bastiaens, A. Wittinghofer, H. Waldmann, 2017, Angewandte Chemie.